⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

October 1, 2024

Supplementary Figure S1 from The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol

Laurien J. Zeverijn Birgit S. Geurts Thomas Battaglia Jade M. van Berge Henegouwen Gijs F. de Wit Louisa R. Hoes Hanneke van der Wijngaart Vincent van der Noort Paul Roepman Wendy W.J. de Leng Anne M.L. Jansen Myriam Chalabi Carla M.L. van Herpen Lot A. Devriese Frans Erdkamp Mariëtte Labots Maja J.A. de Jonge Emile D. Kerver Adriaan D. Bins Lindsay V.M. Leek Jessica C.L. Notohardjo Alfons J.M. van den Eertwegh Lodewyk F.A. Wessels Henk M.W. Verheul Hans Gelderblom Joris van de Haar Emile E. Voest

View at Publisher

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

Supplementary Figure S1. Accrual flowchart including reasons for ineligibility.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zeverijn et al. (2024) studied this question.

synapsesocial.com/papers/68e56226e2b3180350efee97 https://doi.org/10.1158/1078-0432.27142402

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S2 from The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol2024
2Supplementary Figure S3 from The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol2024
3Data from The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol2024
4The innate immune landscape of dMMR/MSI cancers predicts outcome of nivolumab treatment: results from the Drug Rediscovery Protocol2024 · 7 citations
5Integrated analysis of two phase 2 trials of nivolumab in metastatic rare solid cancer with dMMR or pMMR (MASTER KEY sub-studies: ROCK and ROLL trial).2024
6Supplementary Figure S1 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial2025
7Supplemental Figure 2 from Transcriptomic Signatures of MSI-high Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors2024
8Supplementary Figure S2 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-0472025